This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D filed by William H. Lyon and Lyon Shareholder 2012, LLC (“Lyon Investor”, and together with Mr. Lyon, the “Reporting Persons”) with the Securities and Exchange Commission (the “SEC”) on June 24, 2013, as amended by Amendment No. 1 filed on December 14, 2017. This Amendment No. 2 amends and supplements the Schedule 13D as specifically set forth herein.
All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 4. | Purpose of Transaction |
Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows:
Grant of a Limited Waiver Under Section 203 of the Delaware General Corporation Law
On May 1, 2019, the Board of Directors (the “Board”) of William Lyon Homes (the “Issuer”) approved a limited waiver (the “Limited Waiver”) solely for purposes of Section 203 of the Delaware General Corporation Law (the “DGCL”) to allow Mr. Lyon, the Lyon Investor and The William Harwell Lyon Separate Property Trust (the “Lyon Separate Property Trust”, and together with Mr. Lyon and the Lyon Investor, the “Lyon Family Stockholders”) to enter into certain agreements, arrangements and/or understandings (“Section 203 Agreements”) with potential unaffiliated co-investors in connection with evaluating, supporting, developing, or making a potential proposal (a “Proposal”) for a possible business combination with the Issuer. As a result of any possible Section 203 Agreements, a potential unaffiliated co-investor could be considered a non-approved “interested stockholder” for purposes of Section 203 of the DGCL and otherwise subject to the restrictions on “business combinations” under Section 203 of the DGCL. Therefore, in the interests of preserving the ability of the Issuer to enter into potential business combinations that the Board may determine to be in the best interests of the Issuer and its stockholders, the Board granted the Limited Waiver.
The Limited Waiver covers the approval of the entry by the Lyon Family Stockholders into Section 203 Agreements, which may be requested by the Lyon Family Stockholders from time to time, with persons or entities that are approved in advance by the Board (or any committee thereof that is expressly authorized to approve such actions by the Board) and that enter into a standstill and confidentiality agreement with the Issuer in a form acceptable to the Board (or an authorized committee thereof). In addition, the Limited Waiver does not approve the voluntary acquisition by a potential co-investor of any equity securities of the Issuer; however, any recapitalization or merger transaction effected by the Issuer, the formation of a “group” between the Lyon Family Stockholders and a potential co-investor, or any business combination that results from a Proposal approved by the Board, shall not constitute a voluntary acquisition.
The Limited Waiver shall be automatically withdrawn and revoked on May 1, 2020 (the “Anniversary Date”), provided that if, prior to such Anniversary Date, the Lyon Family Stockholders and a potential co-investor have entered into any written Section 203 Agreements with respect to a Proposal, such agreements shall continue to be deemed to be approved for purposes of Section 203 of the DGCL until the date that is the earliest of (a) the consummation of the business combination contemplated by a definitive agreement with respect to such Proposal, (b) the termination of the applicable Section 203 Agreements in accordance with their terms, or (c) 180 days after the Anniversary Date.
Confidentiality Agreement
In addition, on May 1, 2019, and as a condition to the effectiveness of the Limited Waiver, the Lyon Family Stockholders entered into a Confidentiality Agreement with the Issuer (the “Confidentiality Agreement”) that includes customary provisions governing the treatment of confidential information about the Issuer and a standstill provision pursuant to which the Lyon Family Stockholders agreed that until the earlier of (i) one year from the date of the Confidentiality Agreement (or if prior to one year from the date of the Confidentiality Agreement, the Lyon Family Stockholders have entered into, and provided written notice to the Issuer of, a written agreement, arrangement, and/or understanding with a potential co-investor with respect to a potential transaction with the Issuer, 18 months from the date of the Confidentiality Agreement), or (ii) the execution of a final definitive agreement with respect to a negotiated business combination between the Issuer and the Lyon Family Stockholders and their affiliates, unless specifically invited in writing by the Board, neither the Lyon Family Stockholders nor any of their representatives acting on their behalf or on behalf of other persons acting in concert with them will in any manner, directly or indirectly, effect or seek, offer or propose to effect, or announce any intention to effect or cause or participate in: (a) any voluntary acquisition of (1) any securities (or beneficial ownership thereof) of the Issuer in excess of any such securities beneficially owned by the Lyon Family Stockholders as of the date of the Confidentiality Agreement, other than acquisitions of Class B Common Stock pursuant to the exercise of the Class B Warrant or preemptive rights under the Issuer’s Amended and Restated Certificate of Incorporation or acquisitions pursuant to equity awards granted by the Issuer or the exercise of equity awards held by the Lyon Family Stockholders, or (2) any material assets, indebtedness or businesses of the Issuer; (b) any tender offer or exchange offer, merger or other business combination involving the Issuer or any material assets of the Issuer; (c) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Issuer or any of its affiliates; (d) any solicitation of proxies or consents to vote any voting securities of the Issuer or any of its affiliates, except in Mr. Lyon’s capacity solely as an officer or director of the Issuer on behalf of the Issuer; (e) any action, whether alone or in concert with others, to seek or obtain additional representation on the Board or, to seek to advise or influence any person with respect to the voting of any voting securities of the Issuer; or (f) any action which would or would reasonably be expected to force the Lyon Family Stockholders, their representatives, or the Issuer to make a public announcement regarding any of the types of matters set forth in the foregoing.
The foregoing description of the Confidentiality Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Confidentiality Agreement, which is filed as Exhibit J hereto and is incorporated herein by reference.